<DOC>
	<DOCNO>NCT01657851</DOCNO>
	<brief_summary>Open-label , randomize , single dose , two-treatment , two-way crossover study</brief_summary>
	<brief_title>Bioequivalence - Duodart Against Avodart &amp; Omnic</brief_title>
	<detailed_description>The present study plan establish bioequivalence Duodart® 0.5mg/0.4mg manufacture GlaxoSmithKline concomitant dose separate capsule dutasteride 0.5 mg tamsulosin hydrochloride 0.4 mg formulation commercially available Russia . The design present study relies data obtain pivotal bioequivalence study Russian guidance high quality bioequivalence study . Summary treatment group Treatment Sequence Number subject 1 . 18 2 . 18 Total number subject 36 Eligible subject admit research unit one day prior dose ( Day 0 ) remain inpatient approximately 72 hour dose . Subjects undergo washout period approximately 28 day dose study medication . During washout period subject contact via telephone within approximately 10-14 day dose collection information adverse event medication take volunteer washout period Overall study duration could 2 month - Screening 21 day + 10 day ( 5 day 2 treatment period ) + 28 day washout period treatment administration + 10-14 day follow period . Upon completion last dosing session , subject contact via telephone within approximately 10-14 day follow-up inquiry ( visit discretion investigator ) subsequently discharge study . - Order Assessments Procedures Where multiple measurements/evaluations schedule time measurements/evaluations take follow order : 1 . Vital Signs 2 . Orthostatic Vital Signs 3 . PK - Blood Sample Where multiple measurements/evaluations schedule time study co-coordinator attempt ensure PK sample draw close schedule time possible whilst adhere order assessment describe . - Blinding Randomisation On Day 0 first treatment period , subject randomly allocate ratio 1:1 one 2 treatment ( refer Table 1 ) , accord computer-generated randomisation list . CRO generate randomisation list . For purpose randomisation screen number volunteer use ; randomisation number assign study subject . Treatment open-label ; therefore , blind procedure applicable . - Number Subjects Approximately 50 healthy male subject screen allow 36 eligible subject randomize ensure 30 subject complete study accord protocol without violation . - PHARMACOKINETIC PARAMETERS - Drug assay Dutasteride tamsulosin extract human plasma liquid-liquid extraction use organic solvent . Extracts analyse validated high-performance liquid chromatography - mass spectrometry . The low limit detection 0.1ng/mL - Calculation Pharmacokinetic Parameters Pharmacokinetic parameter compute subject treatment use standard method describe Appendix II . For tamsulosin , follow PK parameter compute : - Cmax - Tmax - AUC ( 0-t ) - AUC ( 0-∞ ) - Half-life - Mean residence time For dutasteride , follow PK parameter compute : - Cmax - Tmax - AUC ( 0-t ) - Mean residence time The half-life AUC ( 0-∞ ) compute tamsulosin duration sample period equal 72 h expect non-sufficient reliable computation half-life AUC ( 0-∞ ) dutasteride give complex pharmacokinetics dutasteride long half-life dutasteride two elimination pathway [ 12 ] . - ADVERSE EVENTS ( AE ) AND SERIOUS ADVERSE EVENTS ( SAE ) The investigator site staff responsible detecting , document report event meet definition AE SAE . AEs collect start Study Treatment follow-up contact . SAEs collect time period state AEs . However , SAEs assess related study participation ( e.g . study treatment , protocol-mandated procedure , invasive test , change exist therapy ) relate GSK product record time subject consent participate study include follow-up contact . All SAEs record report GSK within 24 hour - LIFESTYLE AND/OR DIETARY RESTRICTIONS - Meals meal composition Subjects require fast approximately 10 hour prior dose , exception water , allow freely except 1 hour 1 hour dosing . Following dosing , subject allow food 4 hour post dose . Meals serve time outlined Section 2 ( Schedule Assessments ) , seat position ( unless orthostasis detect , meal serve semi-recumbent position ) . Meals serve Days 2 3 approximately time Day 1 . Subjects allow consume follow food drink within 7 day prior first dose study medication collection final pharmacokinetic blood sample : grapefruit juice ; red wine ; grapefruit cruciferous vegetable ( watercress , broccoli , cabbage , Brussels sprout ) . - Dosage Administration One Duodart® 0.5mg/0.4mg capsule Test formulation one Avodart® 0.5 mg one Omnic® 0.4 mg capsule Reference formulation administer morning Day 1 study period . The capsule open chew , swallow whole 200 mL water room temperature - STATISTICAL METHODS - Population analysis For pharmacokinetics parameter calculation statistical analysis , data receive less 30 volunteer complete study accord Protocol explore . Safety analysis population study consist volunteer take part least one study stage . Data volunteer discontinue study prematurely include final report , include pharmacokinetics parameter calculation statistical analysis . If volunteer take study drug , his/her data include statistical analysis . - Analysis Method For pharmacokinetics parameter calculation , statistical analysis , result presentation statistical package ( Statistics , Microsoft Excel 2007 , SAS , SPSS ) use . Descriptive statistic use present mean value , standard deviation , median value , minimal maximal value . Analysis variance do base assumption log-normal distribution AUC , Cmax , Cmax/AUC , normal distribution pharmacokinetics parameter except tmax . The comparison average value investigate comparator drug parameter perform multiplicative model basis confidence interval build ratio correspond mean value . After logarithmic transformation value analyze analysis variance ( ANOVA ) .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Willing able give write informed consent Males 18 45 year age , inclusive Verified diagnosis `` healthy '' Body mass index 2025 kg/m2 ( inclusive ) Negative result test HIV , syphilis , hepatitis B ( HBs Ag ) hepatitis C Adequate , liver , renal function adequate contraception Poor metabolizer CYP2D6 Medical history allergy Medical history medicine intolerability Chronic diseases History surgery gastrointestinal tract History prostate cancer History breast cancer Acute infectious disease Regular use drug Intake medicine high influence liver function haemodynamics Use drug influence activity CYP2D6 CYP3A4 Use Dutasteride le 6 month study entry alphablockers less 2 week study entry Blood donation ( ≥450 mL blood plasma ) less 2 month study start History regular alcohol consumption A positive urine drug alcohol Smoking 10 cigarette day Participation Phase I clinical trial le 3 month study entry History postural hypotension , dizziness , poor hydration , vertigo , vasovagal reaction sign symptom orthostasis Subjects consume follow food drink within 7 day prior first dose study medication time clinical phase study : grapefruit juice ; red wine ; grapefruit cruciferous vegetable ( watercress , broccoli , cabbage , Brussels sprout ) . QTc ≥ 450 msec screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>